CURRENT LANDSCAPE FROM CLINICAL TRIALS AND FUTURE OF COMBINED CHECKPOINTS BLOCKADE IMMUNOTHERAPY IN CANCERS
AbstractImmunotherapy is among cancer immunology’s fastest and most furious treatment strategies. The therapeutic perspective of checkpoint inhibitors is represented through the Food and Drug Administration (FDA) approvals for their implementation in various malignancies. Efforts to improve results with immunotherapeutic agents have led to the design of advanced treatment strategies. Current pre-clinical evidence estimating immune checkpoint inhibitors in several cancer cell lines has recommended that combinatorial approaches may have better survival results than monotherapy. Experimental trials evaluating combined therapy with anti-PD-1/ PD-L1 plus anti-CTLA-4 checkpoint inhibitors have reported considerable leads in survival indices over single immunotherapy. The therapeutic prospective of combinatorial approaches is focused on nivolumab with ipilimumab for advanced melanoma patients. Combined checkpoint inhibition with anti-PD-1/PD-L1 plus anti-CTLA-4 monoclonal antibodies is being estimated for broadly cancer histological studies.
Download